NCT01074359View on ClinicalTrials.gov

Safety and Efficacy Study of A0001 in Patients With the A3243G Mitochondrial DNA Point Mutation

PHASE2TerminatedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions
Neuromuscular Disease
Interventions
DRUG

A0001 (alpha-tocopherolquinone)

28 days (1.5 g total daily dose) oral A0001 capsules. Treatment taken twice daily with meals.

DRUG

Placebo

28 days of placebo oral capsules. Treatment taken twice daily with meals.

Trial Locations (1)

NE2 4HH

University of Newcastle upon Tyne, Newcastle

Sponsors
All Listed Sponsors
lead

Penwest Pharmaceuticals Co.

INDUSTRY

NCT01074359 - Safety and Efficacy Study of A0001 in Patients With the A3243G Mitochondrial DNA Point Mutation | Biotech Hunter | Biotech Hunter